coin-img-ETHETH+0.36%coin-img-BTCBTC+0.34%coin-img-SOLSOL+0.28%coin-img-USDCUSDC-0.02%coin-img-XRPXRP-0.67%coin-img-TRXTRX-0.18%coin-img-GRAMTONGRAMTON-1.48%coin-img-HYPEHYPE+1.67%coin-img-ETHETH+0.36%coin-img-BTCBTC+0.34%coin-img-SOLSOL+0.28%coin-img-USDCUSDC-0.02%coin-img-XRPXRP-0.67%coin-img-TRXTRX-0.18%coin-img-GRAMTONGRAMTON-1.48%coin-img-HYPEHYPE+1.67%coin-img-ETHETH+0.36%coin-img-BTCBTC+0.34%coin-img-SOLSOL+0.28%coin-img-USDCUSDC-0.02%coin-img-XRPXRP-0.67%coin-img-TRXTRX-0.18%coin-img-GRAMTONGRAMTON-1.48%coin-img-HYPEHYPE+1.67%coin-img-ETHETH+0.36%coin-img-BTCBTC+0.34%coin-img-SOLSOL+0.28%coin-img-USDCUSDC-0.02%coin-img-XRPXRP-0.67%coin-img-TRXTRX-0.18%coin-img-GRAMTONGRAMTON-1.48%coin-img-HYPEHYPE+1.67%

SOPHiA GENETICS Posts Q2 2026 Results

AI Market Summary
SOPHiA GENETICS reported Q2'26 revenue of $23.3m (+27% y/y) with stable net loss and a 27% narrowing in adjusted EBITDA loss, while raising FY'26 revenue guidance to $94–96m. U.S. analytics volumes rose 60% y/y, reinforcing demand momentum in clinical genomics and precision diagnostics. The update is supportive for broader precision-medicine themes, though the direct market-wide impact is limited.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+1.20%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
SOPHiA GENETICS reported second-quarter 2026 results with revenue of $23.3 million, up 27% year over year. Reported gross margin was 64.6%. Net loss came in at $22.4 million, in line with the prior-year period. Adjusted EBITDA loss narrowed 27% to $8.8 million. The company raised its full-year 2026 revenue guidance to $94.0 million–$96.0 million. U.S. analytics volumes increased 60% from a year earlier. SOPHiA GENETICS provides a genomics data analytics platform. Management said the growth reflects expanding demand for clinical precision diagnostics, which is seen as a supportive read-through for precision-medicine themes and related indices such as ONCOLOGY US (ONUS).
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.